GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Asset Turnover

LTR Pharma (ASX:LTP) Asset Turnover : 0.00 (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. LTR Pharma's Revenue for the six months ended in Jun. 2023 was A$0.00 Mil. LTR Pharma's Total Assets for the quarter that ended in Jun. 2023 was A$4.88 Mil. Therefore, LTR Pharma's Asset Turnover for the quarter that ended in Jun. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. LTR Pharma's annualized ROE % for the quarter that ended in Jun. 2023 was -62.87%. It is also linked to ROA % through Du Pont Formula. LTR Pharma's annualized ROA % for the quarter that ended in Jun. 2023 was -59.66%.


LTR Pharma Asset Turnover Historical Data

The historical data trend for LTR Pharma's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Asset Turnover Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Asset Turnover
- - -

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Asset Turnover - - -

Competitive Comparison of LTR Pharma's Asset Turnover

For the Biotechnology subindustry, LTR Pharma's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LTR Pharma's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's Asset Turnover distribution charts can be found below:

* The bar in red indicates where LTR Pharma's Asset Turnover falls into.



LTR Pharma Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

LTR Pharma's Asset Turnover for the fiscal year that ended in Jun. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Jun. 2023 )/( (Total Assets (A: Jun. 2022 )+Total Assets (A: Jun. 2023 ))/ count )
=0/( (2.245+7.51)/ 2 )
=0/4.8775
=0.00

LTR Pharma's Asset Turnover for the quarter that ended in Jun. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2023 )/( (Total Assets (Q: Jun. 2022 )+Total Assets (Q: Jun. 2023 ))/ count )
=0/( (2.245+7.51)/ 2 )
=0/4.8775
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


LTR Pharma  (ASX:LTP) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

LTR Pharma's annulized ROE % for the quarter that ended in Jun. 2023 is

ROE %**(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-2.91/4.6285
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2.91 / 0)*(0 / 4.8775)*(4.8775/ 4.6285)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.0538
=ROA %*Equity Multiplier
=-59.66 %*1.0538
=-62.87 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) net income data. The Revenue data used here is two times the semi-annual (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

LTR Pharma's annulized ROA % for the quarter that ended in Jun. 2023 is

ROA %(Q: Jun. 2023 )
=Net Income/Total Assets
=-2.91/4.8775
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-2.91 / 0)*(0 / 4.8775)
=Net Margin %*Asset Turnover
= %*0
=-59.66 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) net income data. The Revenue data used here is two times the semi-annual (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


LTR Pharma Asset Turnover Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


LTR Pharma (ASX:LTP) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines